



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES



Office of Pharmacy Services
Prior Authorization Criteria

Qelbree[®] (Viloxazine)

Effective 9/22/2021

[Prior Authorization Request Form](#)

Qelbree (Viloxazine) is a selective norepinephrine reuptake inhibitor indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age.

CRITERIA FOR APPROVAL :

1. Patient has a diagnosis of attention deficit hyperactivity disorder (ADHD); **AND**
2. Patient is within the age range as recommended by the FDA label; **AND**
3. Patient must have been trialed on maximally tolerated doses of atomoxetine for thirty (30) days and experienced inadequate response or therapeutic failure (unless contraindicated) **OR** Documentation that supports the inability to swallow capsules must be provided (chart notes **AND** current pharmacy claims must reflect the usage of only non-solid or crushable dosage forms); **AND**
4. Patient must have been trialed on one (1) preferred stimulant for thirty (30) days and experienced inadequate response or therapeutic failure (unless contraindicated) **or** patient has a history of illicit substance use **or** household members with a history of illicit substance use **or** there is concern about abuse or diversion.

Approval Duration:

Initial approval will be for 6 months.

Criteria for reauthorization:

1. Demonstrate continued documented compliance; **AND**
2. Documentation of positive clinical response to Qelbree.

Continuation of therapy will be granted for 12 months.



**STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES**



NOTE: "The use of pharmaceutical samples will not be considered when evaluating the members' medical condition or prior prescription history for drugs that require prior authorization."

References:

- 1.) Qelbree Package Insert (9/2021)
- 2.) LexiComp monograph on Qelbree (reviewed 9/2021)
- 3.) UpToDate article: Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents (reviewed 9/2021)